Q2 2026 revenues rose to $13.0B, driven by a 15% YoY increase in the Growth Portfolio and strong product-level performance across oncology, hematology, cardiovascular, immunology, and neuroscience. FY 2026 revenue and EPS guidance were raised, reflecting robust first-half results.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.